Advertisement

Topics

Latest "Odonate Therapeutics" News Stories

02:49 EDT 22nd July 2018 | BioPortfolio

Here are the most relevant search results for "Odonate Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Odonate Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Odonate Therapeutics for you to read. Along with our medical data and news we also list Odonate Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Odonate Therapeutics Companies for you to search.

Showing "Odonate Therapeutics" News Articles 1–25 of 6,400+

Extremely Relevant

Odonate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will present at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018, at 2:30 p.m. Eastern Time. About Odon...


Relevant

Odonate Therapeutics Inc ODT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13032018] Prices from USD $250

SummaryOdonate Therapeutics Inc Odonate, formerly known as Odonate Therapeutics LLC, is a pharmaceutical company which develops medicines for the treatment of cancer. It develops best in class medicines that enhance and extend the lives of patients suffering from cancer. Odonate's lead product candidate, tesetaxel, is a novel orally administered taxane used for the treatment of various cancers. Te...

Odonate Therapeutics Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that there will be two poster presentations on tesetaxel at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 1 – 5, 201...


Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2017. As of December 31, 2017, Odonate had $198.1 million in cash, compared to ...

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2018. As of March 31, 2018, Odonate had $195.2 million in cash, compared to $198.1 mil...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer

- Results from Multicenter Phase 2 Study Presented at The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting - Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that results from a m...

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12.39. The stock Read more...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases Read more...

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Anika Therapeutics currently has a consensus target price of $62.50, indicating a potential upside of 16.84%.

What You Need to Know About DMD Therapeutics

DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.

Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, ...

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics appeared first on Drug Development Technology.

Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics

Celsius Therapeutics has raised $65m in a series A financing round led by Third Rock Ventures with participation from Google Ventures,...Read More... The post Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics appeared first on Drug Development Technology.

Alexion to Acquire Wilson Therapeutics and its Rare Liver Disorder Drug

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Wilson Therapeutics AB (publ) announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. Wilson Therapeutics is a biopharmaceutical com...

UCB and Investor Syndicate Led by Novo Seeds Launch Syndesi Therapeutics to Develop Novel Therapeutics for Cognitive Disorders

LOUVAIN-LA-NEUVE, Belgium, February 8, 2018 /PRNewswire/ -- Syndesi Therapeutics to leverage UCB's expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders wi...

Gain Therapeutics hopes 'pharmacological chaperones' can usher in new therapies for rare diseases

A new firm dubbed Gain Therapeutics has been spun out of Barcelona’s Minoryx Therapeutics, centered…

Novartis, Pear Therapeutics to Develop Digital Therapeutics for Patients With Schizophrenia, MS

NewsNovartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients.

Juno Therapeutics Spinout Raises $90M

JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.

Gilead’s Kite Teams Up with Sangamo Therapeutics for Cancer Therapeutics in a $3.1 Billion+ Deal

Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Abeona Therapeutics Inc: Abeona Therapeutics gibt Finanzergebnisse und Geschäftserfolge des 4. Quartals 2017 bekannt

Telefonkonferenz für Anleger am Dienstag, 27. März um 10.00 Uhr ET NEW YORK und CLEVELAND (USA), 19. März 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), ein führendes, in der kli...

Spark Therapeutics, Inc.: Spark Therapeutics nimmt im März an mehreren Konferenzen teil

PHILADELPHIA, 23. Februar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das sich der Herausforderung in Bezug auf die Unvermeidbarkeit g...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks